Clinical and pathological features are still the best determinants of prognosis in mesothelioma

ONCOLOGY (United States)

Volumn 26, Issue 12, 2012, Pages

  Miller, Andrew C ^a   Hassan, Raffit ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; PEMETREXED; THYMIDYLATE SYNTHASE; TUMOR MARKER;

ARTICLE; CANCER GROWTH; CANCER MORPHOLOGY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; DYSPNEA; GENE EXPRESSION; GENETIC MARKER; HISTOPATHOLOGY; HUMAN; MALIGNANT MESOTHELIOMA; PAIN; PLEURA BIOPSY; PLEURA MESOTHELIOMA; PREDICTIVE VALUE; SURVIVAL PREDICTION; TUMOR BIOPSY;

EID: 84874745986     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Antman K, Shemin R, Ryan L, et al. Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985. J Clin Oncol. 1988;6:147-53.
2. Kao SC, Yan TD, Lee K, et al. Accuracy of diagnostic biopsy for the histological subtype of malignant pleural mesothelioma. J Thorac Oncol. 2011;6:602-5.
3. Greillier L, Cavailles A, Fraticelli A, et al. Accuracy of pleural biopsy using thoracoscopy for the diagnosis of histologic subtype in patients with malignant pleural mesothelioma. Cancer. 2007;110:2248-52.
4. Bueno R, Reblando J, Glickman J, et al. Pleural biopsy: a reliable method for determining the diagnosis but not subtype in mesothelioma. Ann Thorac Surg. 2004;78:1774-6.
5. Gordon GJ, Dong L, Yeap BY, et al. Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma. J Natl Cancer Inst. 2009;101:678-86.
6. De Rienzo A, Dong L, Yeap BY, et al. Fine-needle aspiration biopsies for gene expression ratio-based diagnostic and prognostic tests in malignant pleural mesothelioma. Clin Cancer Res. 2011;17:310-6.
7. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest. 1995;108:1122-8.
8. Rusch VW, Giroux D, Kennedy C, et al. Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database. J Thorac Oncol. 2012;7:1631-9.
9. Pinato DJ, Mauri FA, Ramakrishnan R, et al. Inflammation-based prognostic indices in malignant pleural mesothelioma. J Thorac Oncol. 2012;7:587-94.
10. Nojiri S, Gemba K, Aoe K, et al. Survival and prognostic factors in malignant pleural mesothelioma: a retrospective study of 314 patients in the west part of Japan. Jap J Clin Oncol. 2011;41:32-9.
11. Herndon JE, Green MR, Chahinian AP, et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest. 1998;113:723-31.
12. Suzuki H, Hirashima T, Kobayashi M, et al. Prognostic factors in malignant pleural mesothelioma: a retrospective study. Intern Med. 2012;51:707-10.
13. Kao SC, Vardy J, Harvie R, et al. Health-related quality of life and inflammatory markers in malignant pleural mesothelioma. Support Care Cancer. Aug 31 2012. [Epub ahead of print]
14. Curran D, Sahmoud T, Therasse P, et al. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol. 1998;16:145-52.
15. Zucali PA, Giovannetti E, Destro A, et al. Thymidylate synthase and excision repair cross complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin. Clin Cancer Res. 2011;17:2581-90.
16. Zimling ZG, Sorensen JB, Gerds TA, et al. Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival. J Thorac Oncol. 2012;7:249-56.